Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVP-6308 in schizophrenia
NCT02037074Phase 1Completed
- Sponsor
- FORUM Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EVP-6308 in schizophrenia (4 arms), sponsored by FORUM Pharmaceuticals. Primary endpoint: Safety and tolerability of EVP-6308. Started Jun 2014; status: completed.
02
Drugs
EVP-6308
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02037074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037074.